Recent randomized, controlled trials (RCTs) have analyzed the effect of ketogenic therapies on delaying the progression of the disease and improving cognitive function. A systematic review evaluated the available data on ketogenic therapy and its effect on patients with Alzheimer’s disease and mild cognitive impairment. The researchers concluded that while the research is still in its early stages, ketogenic therapy may hold promise for this patient population.

Eligible studies were published in English and compared the effects of ketogenic therapy versus placebo, usual diet, or meals lacking ketogenic agents on mild cognitive impairment and/or Alzheimer’s disease in adult patients.

Ten RCTs met the eligibility criteria. Interventions were heterogeneous and ranged from 45 to 180 days. They included adherence to a ketogenic diet, intake of ready-to-consume drinks, medium-chain triglyceride (MCT) powder for drinks preparation, yogurt enriched with MCTs, MCT capsules, and ketogenic formulas/meals. Regardless of whether the interventions were acute or long-term, keto neurotherapeutics were correlated with improved general cognition per the Alzheimer’s Disease Assessment Scale-Cognitive.

Read more..

(Visited 54 times, 1 visits today)